OCUL - Ocular Therapeutix

-

$undefined

N/A

(N/A)

Ocular Therapeutix NASDAQ:OCUL Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix's first commercial drug product, DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix has also submitted a Supplemental NDA for DEXTENZA to include the treatment of ocular itching associated with allergic conjunctivitis as an additional approved indication. Ocular Therapeutix's earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases and OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Ocular Therapeutix is currently evaluating each of OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease in Phase 2 clinical trials. Also, in collaboration with Regeneron, OTX-AFS (aflibercept suprachoroidal injection) is in pre-clinical development as an extended-delivery formulation of aflibercept for the treatment of retinal diseases. Ocular Therapeutix's first product, ReSure® Sealant is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.

Location: 24 Crosby Dr, Massachusetts, 01730-1402, US | Website: www.ocutx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.268B

Cash

459.7M

Avg Qtr Burn

-22.22M

Short % of Float

10.66%

Insider Ownership

1.06%

Institutional Own.

92.95%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
DEXTENZA® (dexamethasone ophthalmic insert) Details
Eye disease , Allergic conjunctivitis

Approved

Quarterly sales

ReSure® Sealant Details
Intraoperative management of clear corneal incision

Approved

Quarterly sales

DEXTENZA® (dexamethasone ophthalmic insert) Details
Inflammation and pain following ophthalmic surgery

Approved

Quarterly sales

AXPAXLI (OTX-TKI) (axitinib intravitreal implant) Details
Wet age-related macular degeneration , Eye disease

Phase 3

Data readout

Phase 2

Data readout

Phase 2

Data readout

PAXTRAVA™ (OTX-TIC) (travoprost implant) Details
Ocular hypertension, Primary open angle glaucoma

Phase 2

Update

Phase 1

Data readout